Сравнительная характеристика методов заготовки и клинического применения аферезных концентратов тромбоцитов с использованием добавочного раствора

Использование концентратов тромбоцитов (КТ) нашло повсеместное применение в области онкологии, онкогематологии и трансплантации костного мозга. Одной из основных задач клинической трансфузиологии является разработка и совершенствование технологий, направленных на улучшение качества и безопасности КТ. К таким технологиям относится, в частности, применение добавочных растворов (ДР). Существенными достоинствами этого подхода являются: снижение риска иммунных и неиммунных трансфузионных реакций, повышение качества инактивации патогенов, а также улучшение клинического эффекта трансфузий КТ после хранения. На сегодняшний день предложено большое количество различных ДР и методик их использования. В настоящем обзоре систематизированы современные данные о возможностях применения различных ДР и преимуществах их использования в клинической практике.

1. Румянцев А. Г., Аграненко В. А. Гемотрансфузионная терапия в педиатрии и неонатологии: Руководство для врачей. М.: МАКС Пресс, 2002. 644 с. [Rumyantsev A. G., Agranenko V. A. Transfusion therapy in pediatrics and neonatology: Physicians Guide. M.: MAX Press, 2002. 644 p. (In Russ.)].

2. Slichter S. J., Kaufman R. M., Assmann S. F. et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600–13.

3. Жибурт Е. Б., Мадзаев С. Р. Заготовка и переливание тромбоцитов. М., 2013. С. 116. [Zhiburt E. B., Madzaev S. R. Harvesting and transfusions of platelet. M., 2013. P. 116. (In Russ.)].

4. Донсков С. И., Липатова И. С. Аллоиммунизация антигенами эритроцитов – глобальный популяционный процесс. Гематологический научный центр РАМН РФ. Вестник службы крови России 2001;3:18. [Donskov S. I., Lipatova I. S. Erythrocyte antigens alloimmunization – the global population process. Hematology Research Center of Russian Academy of Medical Science of the Russian Federation. Vestnik sluzhby krovi Rossii = Bulletin of Russian Blood Service 2001;3:18. (In Russ.)].

5. Филатов Ф. П., Голосова Т. В. Общие принципы национальной концепции вирусной безопасности гемотрансфузий. Гематология и трансфузиология 2001;3:84–6. [Filatov F. P., Golosova T. V. The general principles of the national concept of blood transfusions viral safety. Gematologiya i transfuziologiya = Hematology and Transfusiology 2001;3:84–6. (In Russ.)].

6. Абдулкадыров К. М., Бубнова Л. Н. Влияние гемокомпонентной терапии на иммунный статус различных категорий пациентов. Медицинская технология. СПб., 2010. С. 17. [Abdulkadyrov K. M., Bubnova L. N. Influence of blood components transfusion on the immune status of different subgroups of patients. Medical technology. St. Petersburg, 2010. P. 17. (In Russ.)].

7. Глазанова Т. В., Розанова О. Е.,Павлова И. Е. Влияние гемокомпонентной терапии на иммунный статус пациентов с заболеваниями системы крови. Биомедицинский журнал Medline.ru 2011;12:1197–206. [Glazanova T. V., Rozanova O. E., Pavlova I. E. Influence blood components transfusion on the immune status of patients with hematological diseases. Biomeditsinskiy zhurnal Medline.ru = Biomedical Journal Medline.ru 2011;12:1197–206. (In Russ.)].

8. AABB – Association Bulletin #12-04 –Recommendations to Address Residual Risk of Bacterial Contamination of Platelets, October 4, 2012.

9. Corash L. Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis. Expert Rev Hematol 2011;4(5):509–25.

10. Kleinman S., Reed W., Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2013;53(7):1603–18.

11. Sharm S. P. Dengue outbreak affects more than 7000 people in Nepal. BMJ 2010;341:c5496.

12. Stramer S., Hollinger F., Katz L. et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49 Suppl 2:1S–29S.

13. Geiger T. L., Howard S. C. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev 2007;21(1):1–12.

14. Hendrickson J. E., Hillyer C. D. Noninfectious serious hazards of transfusion. Anesth Analg 2009;108(3):759–69.

15. Pelszynski M. M., Moroff G., Luban N. L. et al. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994;83(6):1683–9.

16. Rebulla P. A mini-review on platelet refractoriness. Haematologica 2005;90(2):247–53.

17. Seftel M.D., Growe G. H., Petraszko T. et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004;103(1):333–9.

18. Silliman C. C., Voelkel N. F., Allard J. D. et al. Plasma end lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest 2003;101(7):458–67.

19. McCullough J. Pathogen inactivation: a new paradigm for blood safety. Transfusion 2007;47(12):2180–4.

20. Morel P. C. The French Experience in the Prevention of Transfusion Incidents due to Bacterial Contamination. Bacterial Contamination of Platelets Workshop, Food and Drug Administration, Washington, 1999.

21. Azuma H., Hirayama J., Akino M. et al. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009;49:214–8.

22. de Wildt-Eggen J., Nauta S., Schrijver J. G. et al. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective randomized study. Transfusion 2000;40:398–403.

23. Fontana S., Summermatter R., Vogt M. et al. Comparison of the transfusion efficacy of multiple dose Amicus platelet concentrates collected in plasma or PASIII additive solution. Vox Sang 2011;101s1:135.

24. Goodrich R. P., Edrich R. A., Goodrich L. L. et al. The Antiviral and Antibacterial Properties of Riboflavin and Light: Applications to Blood Safety and Transfusion Medicine. E. Silva, A. M. Edwards (eds.). Flavins: Photochemistry and Photobiology, The Royal Society of Chemistry, Cambridge UK, 2006. Pp. 83–113.

25. Murphy M. F., Waters A. H. Clinical aspects of platelet transfusions. Blood Coagul Fibrinolysis 1991;2(2):389–96.

26. Procházková R., Andrýs C., Hubácková L., Krejsek J. Markers of platelet activation and apoptosis in platelet concentrates collected by apheresis. Transfus Apher Sci 2007;37(2):115–23.

27. Tynngard N., Trinks M., Berlin G. In vitro properties of platelets stored in three different additive solutions. Transfusion 2012;52:1003–9.

28. Holme S. Storage and quality assessment of platelets. Vox Sang 1998;74(2):207–16.

29. Hitzler W. E. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets – significance and assessment of both blood products]. Clin Lab 2014;60(4):S1–39.

30. Hillyer C. D., Shaz B., Zimring J., Abshire T. Component preparation and manufacturing. In: Transfusion medicine and emostasis: clinical and laboratory aspects. Elsevier, First Edition, 2009. Pp. 45–51.

31. Murphy S. Platelets from pooled buffy coats: an update. Transfusion 2005;45:634–7.

32. Council of Europe, Guide to the Preparation, Use and Quality-Assurance of Blood Components, 2013, 17th Edition, Council of Europe Press, Strasbourg, France. P. 335.

33. Kerkhoffs J. L., Eikenboom J. C., Schipperus M. S. et al. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006;108:3210–5.

34. Marschner S., Goodrich R. Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light. Transfus Med Hemother 2011;38(1):8–18.

35. Rebibo D., Simonet M., Hauser L. Introduction of platelet additive solution in platelet concentrates: towards a decrease of blood transfusion reactions. Transfus Clin Biol 2008;15:289–93.

36. de Wildt-Eggen J., Gulliksson H. In vivo and in vitro comparison of platelets stored in either synthetic media or plasma. Vox Sang 2003;84(4):256–64.

37. Gulliksson H. Storage of platelets in additive solutions: a multicentre study of the in vitro effects of potassium and magnesium. Vox Sang 2003;85:199–205.

38. Hirayama J., Azuma H., Fujihara M. et al. Storage of platelets in a novel additive solution (M-sol), which is prepared by mixing solutions approved for clinical use that are not especially for platelet storage. Transfusion 2007;47:960–5.

39. Wagner S. J., Skripchenko A., Myrup A. et al. Calcium is a key constituent for maintaining the in vitro properties of platelets suspended in the bicarbonatecontaining additive solution M-sol with low plasma levels. Transfusion 2010;50:1028–35.

40. Johnson L., Winter K. M., Hartkopf- Theis T. et al. Evaluation of the automated collection and extended storage of apheresis platelets in additive solution. Transfusion 2012;52:503–9.

41. Vasconcelos E. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and apheresis. Transfus Apher Sci 2003;29(1):13–6.

42. Bock M., Rotrig S., Kunz D. et al. Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfus Med 2002;12:317–24.

43. Dumont L., Larry J., Jose A. et al. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion 2013;53:972–80.

44. Metcalfe P., Williamson L. M., Reutelingsperger C. P. et al. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997;98(1):86–95.

45. Vasallo R. R. Rossi, s Principles of Transfusion Medicine, Fourth Edition. Chapter 12. Preparation, Preservation, and Storage of Platelet Concentrates: Platelet Additive Solutions (Synthetic Storage Solutions). T. L. Simon, E. L. Snyder, B. G. Solheim et al. (еds.). Singapore: Wiley- Blackwell, 2009. Pp. 187–98.

46. Folléa G. Homologous platelet concentrates: products available and utilization rules in oncology and haematology. Hematologie 2004;10:233–44.

47. Norol F. Platelet transfusion: a doseresponse study. Blood 1998;92:1448–53.

48. Fontana S., Mordasini L., Keller P., Taleghani B. Prospective, paired crossover comparison of multiple, single-needle plateletpheresis procedures with the Amicus and Trima Accel cell separators. Transfusion 2006;46(11):2004–10.

49. Julmy F., Ammann R. A., Mansouri T. B. et al. Effects of high-yield thrombocytapheresis on the quality of platelet products. Transfusion 2008;48(3):442–50.

50. Шевченко Ю. Л., Жибурт Е. Б. Безопасное переливание крови: руководство для врачей. СПб.: ПИТЕР, 2000. 320 с. [Shevchenko Yu. L., Zhiburt E. B. Safe blood transfusion: Physicians Guide. St. Petersburg: PITER, 2000. 320 p. (In Russ.)].

51. Gulliksson H. Platelets storage media. Transfus Apher Sci 2001;24(3):241–4.

52. Sweeney J., Kouttab N., Holme S. et al. Storage of platelets-rich plasma-derived platelets concentrates pools in plasma and additive solution. Transfusion 2006;46(5):835–40.

53. Wagner S. J., Myrup A., Awatefe H. et al. Maintenance of platelets in vitro properties during 7-day storage in M-sol with a 30-hour interruption of agitation. Transfusion 2008;48(12):2501–607.

54. Sandgren P., Mayaudon V., Payrat J.-M. et al. Storage of buffy-coat-derived platelets in additive solutions: in vitro effects on platelets stored in reformulated PAS supplied by a 20 % plasma carry-over. Vox Sang 2010;98:415–22.

55. Diedrich B., Sandgren P., Jansson B. In vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution. Vox Sang 2008;94(2):96–102.

56. Andreu G., Vasse J., Hervé F. et al. Introduction of platelet additive solutions in transfusion practice. Advantages, disadvantages and benefit for patients. Transfus Clin Biol 2007;14(1):100–6.

57. Жибурт Е. Б., Вергопуло А. А., Губанова М. Н., Копченко Т. Г. Эффективность донорства крови и тромбоцитов в субъектах Российской Федерации. ГлавВрач 2009;2:23–9. [Zhiburt E. B., Vergopulo A. A., Gubanova M. N., Kopchenko T. G. The efficacy of blood and platelets donation in the Russian Federation. GlavVrach = Head Physician 2009;2:23–9. (In Russ.)].

58. Rezza G., Nicoletti L., Angelini R. et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007;370(9602):1840–6.

59. Rinder H. M., Murphy M., Mitchell J. G. et al. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion 1991;31(5):409–14.

60. Cookson P., Sutherland J., Turner C. et al. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfus Med 2010;20(6):392–402.